KH
Ken Haas
OtherActivePartner at Abingworth
68
Investments
0
Exits
—
AUM
0.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Ken Haas.
Investment Thesis & Strategy
Abingworth, with partner Ken Haas, invests in various stages of biotech companies, focusing on those with innovative technologies and the potential for significant impact on human health.
Portfolio Companies
Selected investments from their portfolio of 68 companies
P
Pixium Vision
Other · , 0
R
Reneo Pharmaceuticals
Other · , 0
V
Vera Therapeutics
Other · , 0
P
Portola Pharmaceuticals
Other · , 0
N
Nouscom
Other · , 0
V
Vaxcyte
Other · , 0
L
Lombard Medical plc
Other · , 0
L
Labcyte
Other · , 0
P
Pathwork Diagnostics
Other · , 0
S
Senseonics
Other · , 0
N
Novexel
Other · , 0
C
Clovis Oncology
Other · , 0
Frequently Asked Questions
Ken Haas focuses on Series B stage investments.
Related Investors
Bill Coughran
San Francisco, United States · 104 deals
Dave Lambert
San Francisco, United States · 101 deals
Arun Mathew
San Francisco, United States · 99 deals
Ash Rust
San Francisco, United States · 96 deals
Alex Tran
San Francisco, United States · 95 deals
Randy Williams
San Francisco, United States · 95 deals